Al Altomari, Chairman and CEO
Agile Therapeutics
Charlene Banard, Global Head of Technical Operations Cell & Gene Therapy Strategy, Innovation Pipeline and PMO
Novartis
Jeffrey Berkowitz, Board Member
H. Lundbeck A/S
Liz Bywater, Ph.D., President
Bywater Consulting Group
Ron Cohen, M.D., President & CEO
Acorda Therapeutics
Laurie Cooke, CEO
Healthcare Businesswomen's Association (HBA)
John Crowley, Chairman and CEO
Amicus Therapeutics
Rich Daly, Chief Operating Officer
Beyond Spring
Raúl Díaz, Animal Health Large Molecules Biopharm. Operations
MSD, Montes Claros, MG, Brazil
Tom Dilenge, President, Advocacy, Law & Public Policy Division
Biotechnology Innovation Organization
Joseph Ferra, CFO
Syros Pharmaceuticals
Anu Hans, VP, Strategic Initiatives
Janssen Supply Chain
Fred Hassan, Managing Director
Warburg Pincus
Paul Hastings, President and CEO
Nkarta Therapeutics
Axel Hoos, M.D., Ph.D., SVP Oncology R&D
GSK
John Hubbard, Ph.D., Emeritus Editorial Advisory Board Member
Life Science Leader
Mitchell Katz, Ph.D., Vice President, Development Operations
Ferring Pharmaceutical, Inc.
Mary Rose Keller, VP, Head Of Clinical Operations
Acrivon Therapeutics
Rachel King, CEO
GlycoMimetics
Suresh Kumar, Former EVP External Affairs
Sanofi
John LaMattina, Ph.D., Sr. Partner
PureTech Health
Jacks Lee, SVP Global Manufacturing and Supply
Merck
Martin Lehr, CEO
Context Therapeutics
Sandy Macrae, Ph.D., President & CEO
Sangamo Therapeutics
Ken Moch, Former President & CEO
Cognition Therapeutics
Carol Nacy, Ph.D., CEO
Sequella
Francois Nader, M.D., Chairman of the Board
Acceleron Pharma
Sandra E. Poole, Chief Operating Officer
Mythic Therapeutics
Dennis Purcell, Founder & Sr. Advisor
Aisling Capital
David Pyott, Chairman of the Board
Bioniz Therapeutics
Chandra Ramanathan, Ph.D., MBA, VP & Head, East Coast Innovation Center
Bayer
Stephen Rapundalo, Ph.D., President & CEO
MichBio
Pamela Reilly Contag, Ph.D., Cofounder and CEO
BioEclipse Therapeutics
John Reynders, Ph.D., VP, R&D Strategy, Program Management, and Data Sciences
Alexion
James Robinson, Emeritus Editorial Advisory Board Member
Life Science Leader
Tomasz Sablinski, M.D., Ph.D., Managing Director, Head of Clinical Development
Auven Therapeutics
Jim Scibetta, CEO
Maverick Therapeutics
Chhaya Shah, SVP Technical Operations
Radius Health
Allan Shaw, Independent Consultant
Brandi Simpson, VP Business and Corporate Development
Voyager Therapeutics
Andrew Skibo, Emeritus Editorial Advisory Board Member, Life Science Leader
MedImmune / AstraZeneca
Jason Urban, Ph.D., Sr. Dir. Quality Risk Management
Alexion
Thomas Wiggans, Founder, CEO, Chairman
Dermira
Leslie Williams, Entrepreneur, Executive, Board Member, Mentor
Tim Wright, CEO
MiMedx

IN THIS MONTH'S ISSUE

  • From Academia to Industry – How Biopharma Entrepreneurship Became A Calling
    6/1/2021

    While I knew that I wanted to dedicate my life to developing gene therapies to cure human diseases, I could not have predicted that I would leave academia to become an entrepreneur.

  • How To Identify Capital To Fund Life Sciences Growth
    6/1/2021

    For life sciences companies, funding needs evolve at every stage of growth — creating both challenges and opportunities. Regardless of the stage, it is fundamental to align your funding strategy with your company’s vision.

  • Don’t Overlook The Risks Of Innovative Clinical Trials
    6/1/2021

    Advancements in AI and machine learning (ML) for data collection and interpretation could increase the threat of cyber-attacks and malicious hacking of private medical data. As such, sponsors shouldn’t overlook the liability risk of such advancements and the corresponding changes that should be made to business insurance.

  • Readying For Commercialization
    6/1/2021

    Commercialization planning is particularly important in today’s continuously evolving biopharma marketplace. Not only do you have to manage and allocate capital appropriately but also manage and mitigate the inherent risks in the process — to the extent possible.

@LIFESCILEADER1